Abstract: Disclosed are a process for the preparation of a compound represented by the formula (1), which comprises treating a compound represented by the formula (2) with methanesulfonic acid and then subjecting the thus-treated compound to recrystallization; and Compound (1) so obtained. This Compound (1) is free of hygroscopicity, excellent in filterability and solubility and easy in handling. Furthermore, according to the preparation process of the present invention, an unnecessary isomer can be converted into the target one and separation of the target isomer can be conducted easily.

Abstract: Disclosed are a process for the preparation of a compound represented by the formula (1), which comprises treating a compound represented by the formula (2) with methanesulfonic acid and then subjecting the thus-treated compound to recrystallization; and Compound (1) so obtained. This Compound (1) is free of hygroscopicity, excellent in filterability and solubility and easy in handling. Furthermore, according to the preparation process of the present invention, an unnecessary isomer can be converted into the target one and separation of the target isomer can be conducted easily.

Abstract: Disclosed are a process for the preparation of a compound represented by the formula (1), which comprises treating a compound represented by the formula (2) with methanesulfonic acid and then subjecting the thus-treated compound to recrystallization; and Compound (1) so obtained.

Abstract: An anhydrous crystal of a compound represented by the formula: R2—CH2CONH—R1 wherein R1 represents a substituted or non-substituted pyridyl group or substituted or non-substituted phenyl group and R2 represents a substituted or non-substituted 2-oxo-1-pyrrolidinyl group, characterized in that said crystal is substantially free from hygroscopicity. For example, by drying a hydrous crystal of said compound at a temperature of 80° C. or above under reduced pressure, an anhydrous crystal is provided that exhibits a weight increase of 1% or less when stored under the relative humidity of 83% at the temperature of 25° C. for 30 days. By using the anhydrous crystal for the manufacture of a medicament comprising the compound as an active ingredient, a product with a constant content of the active ingredient can be obtained.

Abstract: Crystals of 3-?2-?4-(3-chloro-2-methylphenyl)-1-piperazinyl!ethyl!-5,6-dimethoxy-1-(4- imidazolylmethyl)-1H-indazole dihydrochloride which is a hydrate for pharmaceutical use having excellent characteristics as a pharmaceutical material that has high storage stability and which substantially has specified X-ray diffraction characteristics, more particularly, the dihydrochloride is 3.5-hydrate.